3-cyano-N-[2-(4-propan-2-ylphenyl)ethyl]benzenesulfonamide | 1026096-35-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3-cyano-N-[2-(4-propan-2-ylphenyl)ethyl]benzenesulfonamide
• CAS: 1026096-35-4
• 化学式: C₁₈H₂₀N₂O₂S
• 分子量: 328.435
• InChiKey: OPVFTPFTJQSBCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  78.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-cyano-N-[2-(4-propan-2-ylphenyl)ethyl]benzenesulfonamide 以 甲醇 为溶剂， 生成 3-amidino-N-[2-(4-isopropylphenyl)ethyl]benzenesulfonamide hydrochloride
  参考文献：
  名称：

  EP1174421

  摘要：

  公开号：
• 作为产物：
  描述：

  2-(4-异丙基苯基)乙胺 、 3-氰基苯磺酰氯 以 四氢呋喃 、 水 为溶剂， 生成 3-cyano-N-[2-(4-propan-2-ylphenyl)ethyl]benzenesulfonamide
  参考文献：
  名称：

  Orally active factor Xa inhibitors: Investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy

  摘要：

  A series of novel and potent 3-amidinophenylsulfonamide derivatives of factor Xa inhibitors were designed and synthesized using an amidoxime prodrug strategy. We focused on systemic clearance of parent compounds in rats, and performed in vivo pharmacokinetic screening. Incorporation of a carboxymethoxy group markedly improved systemic clearance (compound 43), and the related amidoxime 44 showed sufficient prodrug conversion. Compound 45, the double prodrug of 43, exhibited practicable bioavailability after oral administration in rats. Among the various compounds under investigation, KFA-1982 was selected for clinical development. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.009

文献信息

• Orally active factor Xa inhibitors: Investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy
  作者：Masahiko Uchida、Kosuke Okazaki、Harunobu Mukaiyama、Hidetoshi Isawa、Hiroaki Kobayashi、Hiroaki Shiohara、Hideyuki Muranaka、Yuichiro Kai、Norihiko Kikuchi、Hideki Takeuchi、Kenji Yokoyama、Eiichi Tsuji、Tomonaga Ozawa、Yuji Hoyano、Takashi Koizumi、Keiko Misawa、Kiyoto Hara、Shigeru Nakano、Yasuoki Murakami、Hiroaki Okuno

  DOI：10.1016/j.bmcl.2008.07.009

  日期：2008.8

  A series of novel and potent 3-amidinophenylsulfonamide derivatives of factor Xa inhibitors were designed and synthesized using an amidoxime prodrug strategy. We focused on systemic clearance of parent compounds in rats, and performed in vivo pharmacokinetic screening. Incorporation of a carboxymethoxy group markedly improved systemic clearance (compound 43), and the related amidoxime 44 showed sufficient prodrug conversion. Compound 45, the double prodrug of 43, exhibited practicable bioavailability after oral administration in rats. Among the various compounds under investigation, KFA-1982 was selected for clinical development. (C) 2008 Elsevier Ltd. All rights reserved.
• EP1174421
  申请人：——

  公开号：——

  公开（公告）日：——